Core Insights - NeOnc Technologies Holdings, Inc. is expanding its operations into the Middle East through strategic partnerships and governance enhancements [1][2][3] Group 1: Strategic Developments - NeOnc's subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), enhancing its clinical development capabilities [1][3] - The partnership with IROS, part of the M42 group, provides access to a world-class health ecosystem, facilitating accelerated clinical trials for NeOnc's cancer therapies [3][5] - NuroMENA is expanding its Board of Directors to include key partners from Quazar Investment, aiming to strengthen regional governance and growth [2][4] Group 2: Leadership and Governance - The new board members include Waleed K. Al Ali, CEO of Quazar Investment, enhancing the leadership team overseeing NuroMENA's regional strategy [4] - The board will work alongside existing directors to establish a strong foundation for operational excellence and strategic leadership in the Middle East [5] Group 3: Clinical and Research Capabilities - IROS is recognized for its commitment to advancing clinical research and real-world evidence, leveraging cutting-edge technologies to drive innovation [6][7] - The partnership with IROS is expected to enable NeOnc to conduct clinical trials with exceptional speed, quality, and integrity, positioning Abu Dhabi as a global hub for oncology innovation [5][6] Group 4: Company Background - NeOnc Technologies is focused on developing therapies for central nervous system cancers, with its NEO™ drug development platform producing novel drug candidates [11] - The company’s therapeutics, NEO100™ and NEO212™, are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [11]

Core Insights - New to The Street is set to broadcast a nationwide episode on Fox Business featuring interviews with innovative companies such as NeOnc Technologies, FLOKI, XION, Sharps Technology, and Aeries Technology, focusing on their growth and leadership in their sectors [1][2]. Group 1: Company Highlights - The episode will showcase NeOnc Technologies (NASDAQ:NTHI), FLOKI, XION, Sharps Technology (NASDAQ:STSS), and Aeries Technology (NASDAQ:AERT), emphasizing their innovations and market positions [1]. - New to The Street aims to spotlight cutting-edge companies and emerging leaders through investor-focused interviews [2]. Group 2: Programming and Reach - The broadcast is presented as sponsored programming, supported by national TV commercials, enhancing visibility for featured companies [3]. - New to The Street has been a premier platform for corporate storytelling for over 16 years, providing exposure on Fox Business and Bloomberg TV, and has a significant digital presence with over 3.5 million YouTube subscribers [4].

Core Insights - NeOnc Technologies Holdings, Inc. has announced a significant milestone in its partnership with Quazar Investment, with a $50 million strategic partnership set to close by October 23, 2025 [1][4] - The partnership aims to enhance clinical trials, regulatory filings, and infrastructure development in the UAE and the broader MENA region [2][3] Company Overview - NeOnc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers, with a drug development platform that includes NEO100 and NEO212, both in Phase II clinical trials [5] - The company has a patent portfolio extending to 2038, covering various drug candidates and delivery methods [5] Partnership Details - The partnership with Quazar Investment, a prominent Abu Dhabi-based firm with over $3.3 billion in assets, includes a $15 million allocation for Phase 2B clinical trials and infrastructure development [4] - NuroMENA Holdings, NeOnc's subsidiary, was incorporated in the Abu Dhabi Global Market on August 6, 2025, fulfilling the requirements for the partnership [3]

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. David M. Ashley to its scientific advisory board, enhancing its expertise in neuro-oncology [2][3] - Dr. Ashley is recognized for his significant contributions to brain tumor immunology and epigenetics, which will strengthen NeOnc's clinical pipeline, particularly its lead candidates NEO100™ and NEO212™ [3][4] - NeOnc is focused on developing therapies for central nervous system cancers, with its NEO™ drug development platform producing novel drug candidates that have shown positive effects in laboratory tests and clinical trials [5] Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company specializing in central nervous system therapeutics, addressing challenges related to the blood-brain barrier [5] - The company’s lead candidates, NEO100™ and NEO212™, are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [5] - NeOnc holds an extensive worldwide patent portfolio licensed from the University of Southern California, covering various uses for its products, including oncological and neurological conditions [5]

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. Alexandra M. Miller to its scientific advisory board, enhancing its expertise in neuro-oncology [2][3] - Dr. Miller's background in developing liquid biopsy assays for CNS tumors will support NeOnc's clinical trials for its therapeutics NEO100™ and NEO212™ [3][4] - The company is expanding its global trial network, with new sites opening in the Middle East and India, indicating growth in its research capabilities [4] Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers, particularly addressing challenges related to the blood-brain barrier [6] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates, with patent protections extending to 2038 [6] - NEO100™ and NEO212™ are currently in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status [6]

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. Henry S. Friedman to its scientific advisory board, enhancing its expertise in neuro-oncology [1][2][4] - Dr. Friedman is a prominent figure in the field, with over 500 peer-reviewed publications and extensive experience in developing therapies for CNS cancers [4] - The company is preparing to publish data from its clinical programs NEO100 and NEO212, which are in Phase II trials and have received FDA Fast-Track and IND status [3][5] Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers, particularly addressing challenges related to the blood-brain barrier [5] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates with patent protections extending to 2038 [5] - NEO100 and NEO212 are proprietary chemotherapy agents that have shown positive effects in laboratory tests and clinical trials for malignant gliomas [5] Leadership and Strategy - The appointment of Dr. Friedman is expected to strengthen the company's pipeline and enhance stakeholder confidence as it advances its clinical programs [2][3] - The company aims to change the future for patients with glioblastoma and other brain cancers through innovative therapies and collaborative research efforts [3][4]

Core Insights - NeOnc Technologies Holdings, Inc. is set to be featured on "Health Uncensored" hosted by Dr. Drew Pinsky, airing on September 25, 2025, which will provide significant national exposure to the company's innovative therapies for CNS cancers [1][10] - The episode will include discussions on NeOnc's NEO™ platform technology, which aims to overcome the Blood-Brain Barrier, and a patient testimonial highlighting the potential impact of NeOnc's drug candidates [2][3] Company Overview - NeOnc Technologies is a clinical-stage biotechnology company focused on developing therapies for central nervous system cancers, particularly malignant gliomas, utilizing its proprietary NEO™ drug development platform [6] - The company has two lead drug candidates, NEO100™ and NEO212™, currently in Phase II and Phase I clinical trials, respectively, both advancing under FDA Fast-Track status [4][6] Recent Developments - NeOnc has secured a $50 million strategic partnership with Quazar Investment to launch a clinical trials platform in the GCC & MENA regions, enhancing its global presence [12] - The company received FDA authorization to proceed with the Phase II clinical trial of NEO212, a first-in-class oral chemotherapy candidate for brain cancer [12] - NeOnc is nearing full enrollment for its NEO100-01 Phase 2a trial, with top-line data expected in early 2026, and the final patient cohort in the NEO212 Phase I trial is on track for completion in 2025 [12] - The company has been added to the Russell Microcap® Index, increasing visibility among institutional investors [12] - NeOnc received $2.5 million in non-dilutive grants from the NIH to advance its NEO212 program, indicating strong external validation of its scientific approach [12]

Core Insights - NeOnc Technologies Holdings, Inc. has received FDA authorization to advance its NEO212-01 clinical trial into Phase IIa/IIb, marking a significant milestone for the company [1][6] - NEO212 is an innovative oral chemotherapy drug that combines Temozolomide with a proprietary molecule, NEO100, aimed at improving treatment outcomes for CNS cancers [3][4] - The Phase II trial will expand patient enrollment across leading U.S. cancer centers, with plans to activate a broad network of premier institutions [5] Company Overview - NeOnc Technologies Holdings, Inc. is a multi-Phase II clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system cancers and other challenging malignancies [7][9] - The company's portfolio includes NEO100 and NEO212, which are backed by proprietary intellectual property and clinical programs [9] Clinical Development Strategy - The NEO212-01 Phase II trial will build on the successful completion of the Phase I dose-escalation study, which demonstrated safe administration of NEO212 at doses up to 810 mg daily [2] - Patient enrollment for the Phase II trial is expected to begin before the end of 2025, with independent review of the recommended Phase II dose currently ongoing [2] Leadership Commentary - Company leadership emphasizes that the advancement to Phase II represents years of innovation and aims to redefine treatment outcomes for brain cancer patients [6] - The mission of the company is to provide hope to brain cancer patients and their families, with NEO212 embodying this vision of combining science and compassion [6]

Core Insights - NeOnc Technologies Holdings, Inc. has successfully acquired an intellectual property portfolio that enhances its capabilities in drug discovery for CNS cancers [1][2][3] - The acquisition includes advanced technologies such as AI, 3D bioprinting, and quantum modeling, which will improve the efficiency and accuracy of therapeutic candidate screening [2][5] - The transaction was valued at $3.5 million, comprising $500,000 in cash and $3 million in common stock [3] Company Developments - The newly acquired technology allows for the creation of patient-derived 3D brain tumor models, facilitating high-throughput screening of drug candidates [2] - NeOnc's integration of this technology into its R&D operations is expected to support its strategic partnership with Quazar Investment Group for advancing clinical trials in the GCC region [3] - Dr. Ishwar K. Puri has joined NeOnc's Board of Directors, bringing significant expertise in research and innovation [4][5] Strategic Implications - The acquisition is seen as a transformative milestone for NeOnc, enabling faster and more humane drug development processes [5] - The technology is anticipated to reduce reliance on animal testing and expand potential applications beyond brain cancer to other neurological diseases [5] - NeOnc's NEO™ drug development platform, which includes NEO100™ and NEO212™, is currently in Phase II clinical trials and has received FDA Fast-Track status [6]

[Introduction and Agreement Overview](index=1&type=section&id=Introduction%20and%20Agreement%20Overview) This section details the parties, effective date, and purpose of the Share Exchange Agreement [Agreement Parties and Effective Date](index=1&type=section&id=Agreement%20Parties%20and%20Effective%20Date) This Share Exchange Agreement, effective August 18, 2025, is between NeOnc Technologies Holdings, Inc and the members of JandB Holdings, LLC - The Share Exchange Agreement is effective as of **August 18, 2025**[2](index=2&type=chunk) - Parties involved are **NeOnc Technologies Holdings, Inc.** (Company) and the members of **JandB Holdings, LLC** (Members)[2](index=2&type=chunk) [Recitals and Purpose of Exchange](index=1&type=section&id=Recitals%20and%20Purpose%20of%20Exchange) The Members collectively own 100% of JandB Holdings, LLC and intend to exchange their interest for 120,000 shares of Company common stock - Members collectively own **100% of the membership interest** in JandB Holdings, LLC[4](index=4&type=chunk) Exchange Share Details | Item | Value | | :--- | :--- | | Number of Exchange Shares | 120,000 | | Agreed Per Share Value | $25 | [Terms of Exchange](index=1&type=section&id=Terms%20of%20Exchange) This section outlines the authorization, issuance, and closing procedures for the share exchange [Authorization and Issuance of Exchange Shares](index=1&type=section&id=Authorization%20and%20Issuance%20of%20Exchange%20Shares) The Company has authorized the issuance of Exchange Shares to Members in return for their Membership Interest in JandB Holdings, LLC - The Company has authorized the issuance of Exchange Shares to the Members[6](index=6&type=chunk) - Members will surrender, transfer, and assign their Membership Interest in JandB Holdings, LLC to the Company in exchange for the Company's issuance of Exchange Shares[7](index=7&type=chunk) [Closing and Delivery Procedures](index=1&type=section&id=Closing%20and%20Delivery%20Procedures) The closing will occur remotely via electronic signatures, with Members delivering transfer acknowledgments and the Company delivering share statements - The closing of the Exchange will take place remotely by the exchange of electronic signatures[8](index=8&type=chunk) - Members are required to deliver an acknowledgment and transfer of membership interests to the Company[9](index=9&type=chunk) - The Company will deliver a statement from its transfer agent representing the Exchange Shares to the Members[9](index=9&type=chunk) [Representations and Warranties](index=2&type=section&id=Representations%20and%20Warranties) This section contains the formal declarations and guarantees made by both the Company and the Members [Company Representations and Warranties](index=2&type=section&id=Company%20Representations%20and%20Warranties) The Company represents it is in good standing, has corporate power to execute the agreement, and that shares will be validly issued - The Company is a duly organized, validly existing, and in good standing corporation under **Delaware law**[10](index=10&type=chunk) - All necessary corporate actions for the agreement and issuance of Exchange Shares have been taken[11](index=11&type=chunk) - The Exchange Shares, when issued, will be **duly and validly issued, fully paid, nonassessable**, and free of Company-imposed liens[12](index=12&type=chunk) [Members' Representations and Warranties](index=2&type=section&id=Members%27%20Representations%20and%20Warranties) Members represent they have authority, are accredited investors, understand the shares are unregistered, and have consulted their own advisors - Members have the necessary power and authority to execute and deliver this Agreement[13](index=13&type=chunk) - Members understand that the Exchange Shares have not been registered under the Securities Act of 1933 and are **accredited investors** as defined in Rule 501(a) of Regulation D[14](index=14&type=chunk) - Members have had a reasonable opportunity to consult with their own legal, tax, and financial advisors and are relying solely on such advisors[15](index=15&type=chunk) [Investment and Sophistication](index=2&type=section&id=Investment%20and%20Sophistication) Members affirm their sophistication, possession of adequate information, and independent decision-making without reliance on the Company's advice - Members are **sophisticated individuals** familiar with similar transactions and have adequate information about the Company's business and financial condition[16](index=16&type=chunk) - Members have made their own analysis and decision to enter into this Agreement independently and without reliance upon the Company[16](index=16&type=chunk) [JandB Assets](index=3&type=section&id=JandB%20Assets) Members warrant that JandB owns all contributed assets and U.S. Patent No. 11,788,057 free and clear of any liens or encumbrances - JandB owns all assets contributed by Members **free and clear of any lien, encumbrance, or other adverse claim**[17](index=17&type=chunk) - Upon acquisition, **U.S. Patent No. 11,788,057** will be owned free and clear of any lien, encumbrance, or other adverse claim[17](index=17&type=chunk) [Restrictions and Miscellaneous Provisions](index=3&type=section&id=Restrictions%20and%20Miscellaneous%20Provisions) This section covers share transfer restrictions and other standard contractual clauses [Limitations on Transfer and Restrictive Legends](index=3&type=section&id=Limitations%20on%20Transfer%20and%20Restrictive%20Legends) Members are restricted from transferring Exchange Shares except in compliance with securities laws, and shares will bear restrictive legends - Members will not assign, hypothecate, donate, encumber, or otherwise dispose of any interest in the Exchange Shares except in compliance with applicable securities laws[18](index=18&type=chunk) - The Exchange Shares will bear restrictive legends stating they have not been registered under the **Securities Act of 1933**[19](index=19&type=chunk) [General Provisions](index=3&type=section&id=General%20Provisions) This section outlines standard clauses including successors, governing law (Delaware), severability, entire agreement, and notice requirements - The Agreement's terms benefit and bind successors and assignees[20](index=20&type=chunk) - The Agreement is governed by the internal laws of the **State of Delaware**[21](index=21&type=chunk) - This Agreement constitutes the entire agreement among the parties and supersedes prior understandings, amendable only by written consent[25](index=25&type=chunk) [Signatures](index=5&type=section&id=Signatures) This section provides the formal execution of the agreement by all involved parties [Company Signature](index=5&type=section&id=Company%20Signature) The Agreement is executed by NeOnc Technologies Holdings, Inc., signed by its President and Executive Chairman - NeOnc Technologies Holdings, Inc. is represented by **Amir Heshmatpour**, President and Executive Chairman[29](index=29&type=chunk) [Members Signatures](index=6&type=section&id=Members%20Signatures) The Members, Ishwar Puri and Beth R. Levinson, have executed the Exchange Agreement - The Members, **Ishwar Puri** and **Beth R. Levinson**, have signed the Exchange Agreement[31](index=31&type=chunk) [Exhibit A: Acknowledgment and Transfer of Membership Interests](index=7&type=section&id=Exhibit%20A%3A%20Acknowledgment%20and%20Transfer%20of%20Membership%20Interests) This exhibit documents the formal transfer of membership interests from each Member to the Company [Ishwar Puri Transfer](index=8&type=section&id=Ishwar%20Puri%20Transfer) Ishwar Puri formally transfers his 50% membership interest in JandB Holdings, LLC to NeOnc Technologies Holdings, Inc., effective August 18, 2025 - Ishwar Puri transfers his **50% membership interest** in JandB Holdings, LLC to NeOnc Technologies Holdings, Inc[35](index=35&type=chunk) - The transfer is effective as of **August 18, 2025**, and accepted by NeOnc Technologies Holdings, Inc[36](index=36&type=chunk)[37](index=37&type=chunk) [Beth R. Levinson Transfer](index=9&type=section&id=Beth%20R.%20Levinson%20Transfer) Beth R. Levinson formally transfers her 50% membership interest in JandB Holdings, LLC to NeOnc Technologies Holdings, Inc., effective August 18, 2025 - Beth R. Levinson transfers her **50% membership interest** in JandB Holdings, LLC to NeOnc Technologies Holdings, Inc[40](index=40&type=chunk) - The transfer is effective as of **August 18, 2025**, and accepted by NeOnc Technologies Holdings, Inc[41](index=41&type=chunk)[42](index=42&type=chunk)